FDA targets anti-diarrhea pills that Pennsylvania doctor calls 'poor man's methadone'

Lehigh Valley Health Network doctor wrote journal article on dangers of anti-diarrhea pills containing loperamide, FDA takes new measures to stem their abuse by opioid addicts. (Ulysses Muñoz / Baltimore Sun video)

An emergency room doctor with Lehigh Valley Health Network in Pennsylvania last year treated two people who nearly died from taking large quantities daily of an over-the-counter anti-diarrhea medication in an effort to get high or stave off the effects of opioid withdrawal.

The two people who overdosed on loperamide, the active ingredient in the anti-diarrhea medication sought by opioid addicts when they cannot get their drug of choice, so alarmed Dr. Kenneth Katz that he contacted a manufacturer of loperamide. He told the company its product represented “a public health hazard.”


To raise awareness on the issue, Katz also co-wrote an article last year about the two near-fatal cases for The Journal of Emergency Medicine.

Last week, the U.S. Food and Drug Administration took steps designed to limit the abuse of loperamide, the active ingredient in anti-diarrheal medications like Imodium.


In a new drug safety warning, the FDA stated the agency continues to receive reports of “serious health problems and deaths with much higher than the recommended doses of loperamide, primarily among people who are intentionally misusing or abusing the product, despite the addition of a warning to the medicine label.”

The campaign for Maryland’s 6th Congressional District — a competitive and crowded race — has become the center of a political debate over the nation's opioid epidemic.

The agency said it will work with loperamide manufacturers to limit the number of doses in a package and by using blister packs to make it more cumbersome to take large quantities of pills.

The FDA said loperamide overdoses accounted for about a dozen deaths across the nation.

Experts say opioid addicts use the widely available anti-diarrhea medication in massive quantities — sometimes taking hundreds of pills — to get high. Loperamide acts on opioid receptors in the gut to slow the movement in the intestines and decrease the number of bowel movements, the FDA states.

In earlier warnings, the FDA stated that taking higher than recommended doses of the medication could cause serious heart conditions that lead to death.

Loperamide is regarded as “a poor man’s methadone,” to help opioid withdrawal symptoms, said Katz, the LVHN doctor.

In the journal article, Katz details the two overdoses he treated without naming the patients.

“It is a case study of two patients who suffered from heart effects of excessive amounts of loperamide use. Each one nearly died,” Katz said. “It comprises the growing literature describing the obvious toxicity of excessive amounts of loperamide, undoubtedly influencing the FDA to issue its warning.”

Katz’s article described two people who overdosed:

• A 28-year-old man with a history of depression and substance-abuse disorder came into the emergency room with shortness of breath and lightheadedness. He “ingested large amounts of loperamide daily,” and was admitted to the intensive care unit and needed an external pacemaker.

• A 39-year-old woman who also suffered from depression and admitted taking large amounts of loperamide daily. She suffered from seizure-like activity and was also admitted to the intensive care unit for treatment.

At a recent City Council hearing, Baltimore Police Commissioner Darryl De Sousa supported his "strong stance" on going after drug dealers in the city by citing overdoses among 11- and 12-year-olds all across the city. That's not happening. A police spokesman said it was "misspeak."

Since treating those two cases, Katz said, he has not treated any others, but that doesn’t mean loperamide isn’t still be abused.


“It could be that some are using less and figuring out how to use loperamide differently as well,” he said. “Remember, there are patients who have died before even receiving medical care, so we in the emergency room might never see them.”

Dr. John Gallagher, president of the Pennsylvania Medical Society’s opioid task force, said he had only heard anecdotal stories of addicts using loperamide when they didn’t have access to street drugs. He said he believed loperamide abuse was not common, since such a large amount would be needed and the “high doesn’t compare to illicit drug use.”

He said the safety measures proposed by the FDA to curb loperamide abuse are similar to the crackdown against Sudafed, a key ingredient to produce methamphetamine.

“Both are valuable drugs that can be diverted for illicit purposes,” Gallagher said.

Katz said he was glad to hear of the FDA’s new guidelines.

“It’s a start, ultimately,” Katz said. “However, I feel loperamide should be moved behind the counter to further lessen its abuse.”

Twitter @pamelalehman

Recommended on Baltimore Sun